Fred Hutch’s Post

What if you could identify and engage exact physicians with a biomarker positive patient within hours of a patient testing positive? Would this help increase your testing rate? Our Clinical Practice Gaps study, published in the JCO Precision Oncology in 2022* revealed that approximately 64% of potentially eligible patients are lost due to gaps in clinical practice along the patient journey. A significant factor in these missed treatment opportunities is the low prevalence of biomarker testing, often linked to insufficient physician awareness. DXRX Physician Engage enables you to deliver timely, relevant and real-world data-driven messages to physicians treating therapy-eligible patients in as little as 24 hours, educating them on your therapy within the critical treatment decision timeframe, leading to increased biomarker testing rates. Don’t miss the critical window of engagement – talk to us about Physician Engage today. Learn more here: https://lnkd.in/dZNqWKgE *(Sadik et al., JCO 2022) #PrecisionMedicine #BetterTesingBetterTreatment

Research continues to deliver new diagnostic tools and treatments in oncology, which could mean better patient outcomes and lower costs. Digital connectivity, alignment to clinical guidelines and collaborative provider relationships can help ensure patients have access to the most clinically appropriate precision testing and therapies faster, while ongoing care management can support patients throughout their journeys and reduce adverse events. Here are a few key insights from CVS Health's recent findings on costs and quality of oncology care released for #ASCO2021. #TeamCVS

Now more than ever, we are reminded how the safety of our ADG126 SAFEbody and its best-in-class profile is translating to better patient outcomes, including clinical response and survival. With a safety profile comparable to pembrolizumab monotherapy, the ADG126 + pembrolizumab doublet is well positioned to become a new cornerstone #IO therapy that can be broadly combined, addressing indications and patient populations beyond the IO agents available today! With its unique mechanism and ability to target CTLA-4 on Tregs in the tumor microenvironment, ADG126 is designed to take #CTLA-4 to a new level. Check out our publications showcasing its 10x higher combination dosing than ipilimumab, and unique ability to dose more frequently @Q3W and repeatedly beyond 4 cycles: https://loom.ly/m_8X16s

Today is the final day to register! You do not want to miss this impactful event. Join C-Path's Cure Drug Repurposing Collaboratory team and CURE ID for a groundbreaking Patient-Powered Research Webinar hosted by the Sarcoma Foundation of America, Thursday, January 18, 1 PM ET. Sarcoma Foundation of America is dedicated to fostering the development of innovative treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force, we are excited to present a pioneering project that delves into the potential of repurposing existing medications for the benefit of sarcoma patients. This initiative is at the forefront of leveraging real-world data from electronic medical records to invaluable insights shared by patients and their healthcare providers. The goal is to illuminate the path to cost-effective treatments, harnessing the power of existing drugs that, while proven safe, require further evidence to support their novel application in sarcoma therapy. Your involvement is crucial in propelling this research forward, paving the way for new, accessible treatment avenues for the sarcoma community. Learn more and register here: https://lnkd.in/gEBVyzdu. Clear Cell Sarcoma Foundation| xCures| Memorial Sloan Kettering Cancer Center| William Tap| Marco Schito| Brandi Felser| Timothy Stuhlmiller| Lennie Woods #CPath #CDRC #CUREID #drugrepurposing #sarcoma #drugdevelopment #datasharing #EHR #collaboration #globalhealth

The advent of #immunotherapy has revolutionized the treatment algorithm in #NSCLC, with practice-changing implications for clinicians and their patients. In metastatic disease, an array of monotherapy and combination options offers unprecedented choices, enabling individualized approaches for each patient. However, unmet needs remain for patients who have progressed or developed resistance in the second line and beyond. Consolidation immunotherapy following chemoradiation represents the standard approach in locally advanced, unresectable, stage III NSCLC, and ongoing studies are expected to further optimize outcomes in this setting. In resectable disease, neoadjuvant, adjuvant, and perioperative immunotherapy continue to shape an evolving care paradigm, and recent practice-changing advances have transformed curative-intent settings. This PeerView Live MasterClass educational symposium will provide comprehensive guidance on the evidence-based integration and practical use of current and emerging immunotherapy options. Illustrative case scenarios will be shared to inform clinical decisions and leverage collaboration among care team members to refine the use of immunotherapy along the NSCLC disease continuum. Join us in person or online during #ASCO24 on June 1 at 6:30 PM CDT. https://bit.ly/2024NSCLCL This activity is supported by independent educational grants from AstraZeneca and Bristol Myers Squibb.

What if you could identify and engage exact physicians with a biomarker positive patient within hours of a patient testing positive? Would this help increase your testing rate? Read the post below 🔽 #precisionmedicine #biomarkers

Experts talk new adjuvant treatment opportunities for NSCLC👇 https://buff.ly/3SP3zLF Listen now as two oncologists evaluate the clinical evidence for newly approved adjuvant #immunotherapies for patients with completely resected #NSCLC #MedEd #LungCancerAwareness #GetYourAnswersinCME

Save the date and save your seat! 🗓️ 🩺 Healthcare Providers: Jan. 17, 2024 @ 5PM ET ctf.org/webinar 💞 Patients & Caregivers: Jan. 18, 2024 @ 8PM ET ctf.org/tunein The Children's Tumor Foundation is hosting this presentation by NFlection Therapeutics to share results from the Phase 2b Study of NFX‑179 Topical Gel in the treatment of cutaneous neurofibromas in neurofibromatosis type 1 with the NF community. #endnf #makenfvisible

ICYMI: We recently released our 2023 Oncology in Diagnostic Imaging Market Outlook Report! This unique report offers a cross-modality view of the Oncology care area and provides healthcare administrators, physicians, and other diagnostic imaging professionals with the information needed to make informed decisions and plans for their facilities. Learn more about what’s included in this report by downloading the table of contents here: https://hubs.la/Q02gZgFW0

#WorldCancerDay 🌐 🎗️ We believe that progress in cancer care is not only driven by medical breakthroughs but also by collaborative efforts between companies, the healthcare community, patient advocacy groups as well as patients and their relatives. We are truly dedicated to helping patients take an active role in managing their disease. Our patient-focused web services for NET patients provide valuable information and tools to support patients and their families on this journey as well as explaining the treatment options with Radiopharmaceutical Therapy (RPT): www.mynetjourney.com 🇪🇺 www.voicesofnet.com 🇺🇸 Radiopharmaceutical Therapy (RPT) has emerged as a groundbreaking approach. 🌱 By combining the precision of radioisotopes with targeting molecules, this technology selectively targets tumor cells while sparing healthy tissue. This innovative method holds the promise of more effective treatments and an improved quality of life for patients. Let’s work together to #CloseTheCareGap 💙 #CancerResearch #RadiopharmaceuticalTherapy #HealthcareInnovation